


# 3<sup>rd</sup> International Michelangelo Conference



FONDAZIONE MICHELANGELO  
avanzamento dello studio e cura dei tumori

## Promises and challenges of developing new drugs in oncology

Chairman: Luca Gianni, Milan I

### July 2-3, 2015

Venue: Museo della Scienza  
e della Tecnologia

Via San Vittore, 21 - 20123 Milan (Italy)

**PRELIMINARY  
PROGRAM**

## Scientific Committee

- **Hilary Calvert**  
UCL Cancer Institute, London, UK
- **Luca Gianni**  
IRCCS Istituto Scientifico San Raffaele, Milan, Italy
- **Lajos Pusztai**  
Yale Cancer Center, New Haven, USA
- **Cristiana Sessa**  
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland - IRCCS Istituto Scientifico San Raffaele, Milan, Italy
- **Josep Taberero**  
Vall d'Hebron University Hospital, Barcelona, Spain
- **Giampaolo Tortora**  
University of Verona, Italy
- **Giuseppe Viale**  
University of Milan, European Institute of Oncology, Milan, Italy

## Scientific Secretariat

- **Giampaolo Bianchini**  
Fondazione Michelangelo, Milan, Italy
- **Angelica Fasolo**  
Fondazione Michelangelo, Milan, Italy

## Faculty

- **Hilary Calvert**  
UCL Cancer Institute, London, UK
- **Luca Gianni**  
IRCCS Istituto Scientifico San Raffaele, Milan, Italy
- **Teemu Junttila**  
Genentech, San Francisco, USA
- **Patricia M. LoRusso**  
Yale Cancer Center, New Haven, USA
- **Gordon Mills**  
Md Anderson, Houston, USA
- **Luigi Naldini**  
IRCCS Istituto Scientifico San Raffaele, Milan, Italy
- **Gail Phillips**  
Genentech, San Francisco, USA
- **Neal Rosen**  
Sloan Kettering Cancer Center, New York, USA
- **Charles Swanton**  
CR-UK / Francis Crick Institute, London, UK
- **Mario Sznol**  
Yale Cancer Center, New Haven, USA



## Welcome address

The 3<sup>rd</sup> International Michelangelo Conference will convene a faculty of leading international experts to discuss new therapeutic opportunities emerging from two different areas of cancer pathology: aberrant cancer cell signaling and control of tumor growth by the immune system.

In recent years, highthroughput technologies have paved the road to “omics” science, and resulted in impressive qualitative and quantitative increase of our understanding of the molecular and biological characteristics of cancer, and of inter- and intra-tumor heterogeneity. Improved knowledge of the molecular mechanisms of cancer has translated into the identification of new therapeutic targets, and the possibility of understanding the pathogenetic role of already established targets of therapy outside the original contest in which they were discovered. Overall this is leading to a paradigm shift in drug development and application that moved from the approach of “one-drug-fits-all” to using drugs tailored to the target. The understanding of the key role of some molecules (e.g. CDK4/6, PARP) in the mechanisms of survival/resistance of some tumors has driven the development of new compounds, which provide significant clinical benefit in selected sub-groups of patients. The comprehensive assessment of the molecular portrait of cancer has allowed to shift the focus from targeting individual molecular aberrations to targeting pathways’ alterations that can be driven by several different individual aberrations. In this context, the emerging appreciation of the intratumor heterogeneity represents a challenge. In addition, the crosstalk existing between various signaling pathways (e.g. RAS-pathway) has indicated the need to combine targeted drugs as a strategy to overcome mechanisms of intrinsic and acquired resistance.

At the same time the long-sought therapeutic exploitation of the immune system in cancer has found correspondence in the development of a new generation of drugs that in part overcome the problem of immune escape and are becoming a major breakthrough in cancer therapy. The immune-checkpoints inhibitors, which allow the immune system to restore its potential activity against tumors, have already shown impressive clinical results in several solid tumors. The activity of engineered immune cells represents another exciting therapeutic strategy. Finally, the rational combination of immunotherapies and standard treatments represents a major challenge, but also a formidable promise for the future of drug therapy of cancer treatment.

### Gianni Bonadonna Prize for New Drug Development in Oncology

On the occasion of the 3<sup>rd</sup> International Conference on “Promises and challenges of developing new drugs in oncology” Fondazione Michelangelo is proud to reconfirm also for this edition, the “Gianni Bonadonna Prize for New Drug Development in Oncology”, aimed to promoting and improving clinical research on the development of novel compounds. The prize of € 20.000,00 will be assigned for an original oncology clinical research project for the development of novel compounds and it is addressed to researchers up to 40 years of age.

**Deadline for Receipt of Applications: May 15, 2015**

**For more information on the criteria to apply to the prize please contact the Scientific Secretariat:  
e-mail: [segreteria@fondazionemichelangelo.org](mailto:segreteria@fondazionemichelangelo.org) – [www.fondazionemichelangelo.org](http://www.fondazionemichelangelo.org)**

### Call for Abstract

Participants can submit abstracts on the main topics of the International Conference before June 1, 2015 to [segreteria@fondazionemichelangelo.org](mailto:segreteria@fondazionemichelangelo.org), filling in the form available on [www.fondazionemichelangelo.org](http://www.fondazionemichelangelo.org)

**Abstracts will be selected for Poster display.**



# Preliminary Program

## Day 1, Thursday, July 2<sup>nd</sup>, 2015

3.00 - 3.15 pm	<b>Welcome</b> L. Gianni
3.15 - 4.15 pm	<u>MAIN LECTURE</u> <b>Clinical results and prospective for CD4/6 inhibitors</b> P. M. LoRusso
4.15 - 5.00 pm	<b>Discussion</b>
5.00 - 6.00 pm	<b>Gianni Bonadonna Prize</b> <b>Presentations of three selected projects</b> <b>Reports of the 2013 winners</b> A. Covre, F. Paduano

## Day 2, Friday, July 3<sup>rd</sup>, 2015

Morning Chair: (TBD)	
9.00 - 9.40 am	<u>Antibody drug-conjugates</u> <b>Challenges and opportunities for HER2-directed antibody-drug conjugates</b> G. Phillips
9.40 - 10.20 am	<u>DNA-interacting agents and PARP inhibitors</u> <b>Biologic rationale and emerging new drugs</b> G. Mills
10.20 - 11.00 am	<b>Current status of PARP and other DNA repair inhibitors</b> H. Calvert
11.00 - 11.20 am	<i>Coffee break</i>
11.20 - 12.10 am	<u>Immunotherapy: the new frontier</u> <b>Opportunities and Challenges for Combinations of Immune Checkpoint Modulators</b> M. Sznol
12.10 -12.40 pm	<b>Bispecific T-cell engaging antibodies</b> T. Junttila
12.40 - 1.15 pm	<b>Discussion</b>
1.15 - 2.15 pm	<i>Lunch</i>
Afternoon Chair: (TBD)	
2.15 - 2.45 pm	<u>Insight in molecular biology</u> <b>Potential clinical implications for target therapies of intratumor heterogeneity</b> C. Swanton
2.45 - 3.15 pm	<b>Evolving concept on targeting signalling pathways</b> N. Rosen
3.15 - 3.30 pm	<b>Discussion</b>
3.30 - 4.15 pm	<u>MAIN LECTURE</u> <b>Engineered cells for cancer therapy</b> L. Naldini
4.15 - 4.30 pm	<b>Discussion</b>
4.30 pm	<b>Gianni Bonadonna Prize</b> <b>The Winner's Ceremony</b>

# Conference General Information

## Conference Venue

### Museo della Scienza e della Tecnologia

Meeting room: Sala delle Colonne (first floor)

Via San Vittore, 21 – 20123 Milan, Italy

 MM2 Sant'Ambrogio

## Dates of the Conference

From Thursday, July 2<sup>nd</sup> to Friday, July 3<sup>rd</sup> 2015.

## CME Accreditation

Application has been made to obtain approval for Italian CME accreditation for the competent bodies.

## Official Language

The official language of the Conference is English.

No translation will be provided.

## Application

Attendance is free of charge, however application is compulsory.

Please send the application form to [michelangelo@newaurameeting.it](mailto:michelangelo@newaurameeting.it) until 19<sup>th</sup> June 2015.

## Accommodation

To require hotel accommodation in Milan, please fill in the application form available on [www.fondazionemichelangelo.org](http://www.fondazionemichelangelo.org); for further information, contact the Organizing Secretary to [michelangelo@newaurameeting.it](mailto:michelangelo@newaurameeting.it)



FONDAZIONE MICHELANGELO  
avanzamento dello studio e cura dei tumori

### Scientific Secretariat

- Giampaolo Bianchini
- Angelica Fasolo

### Fondazione Michelangelo

Via A. Bertani, 14 – 20154 Milano, Italy

Phone +39 02 87086421 – Fax +39 02 87086449

E-mail: [segreteria@fondazionemichelangelo.org](mailto:segreteria@fondazionemichelangelo.org)

[www.fondazionemichelangelo.org](http://www.fondazionemichelangelo.org)



NEW AURAMEETING

### Organizing Secretary

### New Aurameeting Srl

Via Rocca d'Anfo, 7 – 20161 Milan, Italy

Phone: +39 02 66203390 – Fax: +39 02 66200418

Email: [michelangelo@newaurameeting.it](mailto:michelangelo@newaurameeting.it)

[www.newaurameeting.it](http://www.newaurameeting.it)



# Application Form

Please send to New Aurameeting srl – Via Rocca d’Anfo 7, 20161 Milan – Fax: + 39.02.66200418  
email: [michelangelo@newaurameeting.it](mailto:michelangelo@newaurameeting.it) until 19<sup>th</sup> June 2015

Title:  Dr.  Prof.  Mr.  Mrs.

Family Name \_\_\_\_\_ First Name \_\_\_\_\_

Company/Institute \_\_\_\_\_

Address \_\_\_\_\_

ZIP Code \_\_\_\_\_ City \_\_\_\_\_ Country \_\_\_\_\_

e-mail \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

To require Hotel Accommodation in Milan please fill with the following compulsory information:

Check-in: \_\_\_\_\_ Check-out: \_\_\_\_\_ N° nights: \_\_\_\_\_

Hotel Category:  3 stars  4 stars

In Conformity with the legislative decree 196/2003, New Aurameeting will use the personal data supplied only for communications related to the services offered and for administrative processes. For Right of access to personal data and other rights (Art. 7) please write to New Aurameeting Srl, Via Rocca d’Anfo 7, 20161 Milano – [info@newaurameeting.it](mailto:info@newaurameeting.it)




## Useful Information:

**3<sup>rd</sup> International Michelangelo Conference**  
**2 - 3 July 2015**

**Congress Venue:** Museo della Scienza e della Tecnologia

**Meeting room:** Sala delle Colonne (first floor)

Via San Vittore 21, 20123 Milano

 MM2 Sant’Ambrogio

CME Accreditation for the competent bodies

*Attendance is free, however application is compulsory for organizing reason*

**Deadline for registration:** 19<sup>th</sup> June 2015

**Official Language:** English



## Travel Information to reach the Congress Venue:

### By public transport

 Metro M2 Stop S. Ambrogio

Bus 50, 58 stop San Vittore

Bus 94 stop Carducci

### From the railway stations


 **Stazione Centrale FS:** Metro M2 direction Abbiategrasso - 6 stop (station S. Ambrogio)

 **Porta Garibaldi FS:** Metro M2 direction Abbiategrasso - 4 stop (station S. Ambrogio)

 **Stazione Cadorna FN:** Metro M2 direction Abbiategrasso - 1 stop (station S. Ambrogio)

### From the airports

#### Malpensa Airport

 Malpensa Express to “Cadorna - City Centre”, then Metro M2 direction Abbiategrasso - 1 stop (station S. Ambrogio)

#### Linate Airport

Bus 73 to S. Babila then

 Metro M1 direction Bisceglie / Rho-Fiera - 4 stop (station Cadorna) then

 Metro M2 direction Abbiategrasso - 1 stop (station S. Ambrogio)

### By car

The Museum is located in the center of Milan. The exact address is: Via S. Vittore, 21. Arriving by car you can easily park close to the Museum at Carducci Parking in via Olona. Access to the city Center is restricted – Access Toll 5,00 €